VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	11Cr 9.48Cr 8.87Cr 8.11Cr 15Cr 1.06TCr 15Cr 104.93Cr 41Cr 531.78Cr 42Cr 41Cr 1.76TCr	P/E 2026 *	-22.2x	P/E 2027 *	-19.7x
Enterprise Value	11Cr 9.48Cr 8.87Cr 8.11Cr 15Cr 1.06TCr 15Cr 104.93Cr 41Cr 531.78Cr 42Cr 41Cr 1.76TCr	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

14/08	Yarrow Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	RTW Biotech's Avere to go public in US in reverse merger with NextCure	AN
03/08	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
29/07	RTW Biotech's Portfolio Company Completes Merger with Vyne Therapeutics	MT
28/07	Yarrow Bioscience, Inc.(NasdaqCM:YARW) added to NASDAQ Composite Index	CI
27/07	Yarrow Bioscience, Inc. completed the acquisition of VYNE Therapeutics Inc. from AI Biotechnology LLC, Nantahala Capital Management LLC, and other shareholders in a reverse merger transaction.	CI
27/07	Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101	MT
27/07	Yarrow Bioscience, Inc. announced that it has received $200 million in funding from a group of investors	CI
24/07	Top Premarket Decliners	MT
21/07	VYNE Approves 1-for-50 Reverse Stock Split	MT
10/07	VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026	CI
10/07	VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger	MT
16/06	Yarrow Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

03/08	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
31/25/31	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
18/24/18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
12/23/12	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT
14/23/14	HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	MT

13/08	Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update	BU
24/07	VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience	AQ
21/07	VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
10/07	VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
22/05	VYNE Therapeutics : Yarrow Bioscience Investor Presentation	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FOAMIX PHARMACEUTICALS LTD.	-.--%	-16.94%	-	-	1.91Cr
WUXI APPTEC CO., LTD.	+3.31%	-3.53%	+71.28%	+104.57%	6.91TCr
ARGENX SE	+1.74%	+1.06%	+49.02%	+87.38%	6.31TCr
BIONTECH SE	+2.71%	+25.19%	+10.51%	-1.28%	2.83TCr
INSMED INCORPORATED	+1.17%	-2.40%	-2.29%	+474.08%	2.71TCr
WUXI BIOLOGICS (CAYMAN) INC.	+7.41%	+13.08%	+58.57%	+17.04%	2.55TCr
GENMAB A/S	+3.98%	+4.37%	+39.47%	-14.65%	1.97TCr
PHARMAESSENTIA CORPORATION	+1.02%	+5.67%	+273.94%	+420.34%	1.92TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.10%	+0.19%	+12.19%	+550.31%	1.6TCr
EXELIXIS, INC.	+2.63%	+5.38%	+47.70%	+154.57%	1.35TCr
Average	+2.42%	+3.94%	+62.27%	+199.15%	3.13TCr
Weighted average by Cap.	+2.75%	+2.95%	+59.05%	+158.57%

Foamix Pharmaceuticals Ltd. Share Price Nasdaq

Stocks

IL0011334385

Biotechnology & Medical Research

Valuation: Foamix Pharmaceuticals Ltd.

Latest news : Foamix Pharmaceuticals Ltd.

Last Transcript: Foamix Pharmaceuticals Ltd.

Analysts' recommendations: Foamix Pharmaceuticals Ltd.

Press Releases: Foamix Pharmaceuticals Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

	2026 *	2027 *
Net sales	-	-
Net income	-3.85Cr -3.3Cr -3.09Cr -2.83Cr -5.33Cr -369.08Cr -5.39Cr -37Cr -14Cr -185.33Cr -14Cr -14Cr -613.19Cr	-6.69Cr -5.73Cr -5.36Cr -4.9Cr -9.25Cr -640.54Cr -9.35Cr -63Cr -25Cr -321.64Cr -25Cr -25Cr -1.06TCr
Net Debt	-	-